西特制药公司(West Pharmaceutical Services Inc.)24日股价盘中大涨16.93%,此前公司公布第三季度业绩优于预期,并上调了2024年全年盈利和营收预期。
财报数据显示,西特制药第三季度实现营收7.469亿美元,超出分析师预期的7.096亿美元。营收主要来自于专利产品部门6.014亿美元的贡献,也高于预期。经调整后,该公司第三季度实现每股盈利1.85美元,较预期1.50美元有显著增长。
在这一利好消息的刺激下,西特制药上调了2024年全年每股盈利预期至6.55-6.75美元,年营收预期上调至28.8-29.1亿美元。公司营收和利润同步大幅增长,主要得益于全球对诸如诺和诺德肥胖症药物Wegovy、礼来糖尿病药Mounjaro等治疗性药品包装材料的需求大增。分析人士指出,随着药品创新加快推进和生物制药行业持续扩张,作为医疗包装供应商的西特制药具备广阔的发展前景,有望继续保持营收高速增长,被视为值得长期持有的成长型投资标的。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.